Public Advisory - Equate (lemon flavour), Personnelle (lemon flavour) and Life Brand (lemon and cherry flavours) Magnesium citrate oral solution saline laxatives recalled due to potential microbial contamination
OTTAWA, ON, July 24, 2022 /CNW/ -
Summary
Product: Equate (lemon flavour), Personnelle (lemon flavour) and Life Brand (lemon and cherry flavours) Magnesium citrate oral solution saline laxative, lemon and cherry flavours (NPN 80015316)
Issue: Health product ? product safety
What to do: Stop using the recalled product. Speak to a health care professional if you have taken this product and have health concerns.
Health Canada is advising that all lots of Equate (lemon flavour), Life Brand (lemon and cherry flavours) and Personnelle (lemon flavour) Magnesium citrate oral solution saline laxative (NPN 80015316) are being recalled by the importer, Shandex Sales Group Ltd. (Shandex Group), due to the possibility of microbial contamination. The company is recalling the products as a precaution in light of a recall in the United States (U.S.) of similar products that are manufactured at the same site.
Magnesium citrate oral solution is used as a laxative for relief of occasional constipation. The product is indicated for use in adults and children two years of age and older.
Microbial testing of the products recalled in the U.S. identified the presence of Gluconacetobacter liquefaciens. Ingesting contaminated product may result in symptoms including abdominal discomfort or pain, diarrhea, nausea and vomiting. Children, pregnant women, the elderly and people with a weakened immune system may be more susceptible to serious adverse effects from microbial contamination.
The Department is monitoring the company's recall and will inform Canadians if any new health risks are identified.
What you should do
Stop using the recalled product.
Contact your health care practitioner if you have used this product and have concerns about your health.
Contact the importer, Shandex Sales Group Ltd. by calling 1-905-420-7407, or by email at [email protected], if you have questions about this recall.
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...